Basal insulin analogues — Competitive Intelligence Brief

Basal insulin analogues (Basal insulin analogues) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Basal insulin analogue. Area: Diabetes.

marketed Basal insulin analogue Insulin receptor Diabetes Small molecule

Target snapshot

Basal insulin analogues (Basal insulin analogues) — Novo Nordisk A/S. Basal insulin analogues are long-acting insulin formulations that bind to insulin receptors to promote glucose uptake and utilization, providing steady background insulin coverage for blood glucose control.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Basal insulin analogues TARGET	Basal insulin analogues	Novo Nordisk A/S	marketed	Basal insulin analogue	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Basal insulin analogue class)

1. Novo Nordisk A/S · 1 drug in this class